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Search Strategy:  41 
We searched medline (1966 to 31
st
 October 2015) using terms neurodegeneration, 42 
amyotrophic lateral sclerosis, frontotemporal dementia and metabolism in 43 
combination with eating, neuroendocrine, diet, insulin resistance, cholesterol and 44 
lifestyle factors. Further articles were included from reference lists, review articles, 45 
and major textbook chapters. Abstracts and reports from relevant meetings were also 46 
included. The final reference list was generated on the basis of originality and 47 
relevance to the topics. Emphasis was placed on publications from the past 5 years, 48 
but did not exclude commonly referenced and highly regarded older publications. 49 
Only papers published in English were considered in our search. 50 
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Abstract 53 
Metabolic changes incorporating changes in weight, insulin resistance and cholesterol 54 
levels have been identified across a  number of neurodegenerative conditions. It 55 
remains unknown how these changes arise, whether they represent the result of the 56 
process of neurodegeneration affecting critical brain regions involved in metabolic 57 
regulation, or are causative, driving the process. In amyotrophic lateral sclerosis 58 
(ALS) metabolic changes have been linked to disease progression and prognoses. 59 
Changes in eating behaviour affecting metabolism have been incorporated into the 60 
diagnostic criteria for frontotemporal dementia (FTD), which shares a significant 61 
clinical and pathological overlap with ALS.  Given the spectrum of metabolic and 62 
eating changes observed in ALS and FTD, these two conditions may potentially 63 
provide a model to better understand the pathophysiology of metabolic change and to 64 
further study the interplay between systemic metabolism and the process of 65 
neurodegeneration. 66 
 67 
Introduction 68 
 69 
Increasing evidence suggests that metabolic change, including fluctuations in weight, 70 
insulin resistance and cholesterol has an increased incidence across a range of 71 
neurodegenertive conditions
1,2-5
. It remains to be clarified how these changes may 72 
modulate the process of neurodegeneration and indeed how they may affect disease 73 
progression and thereby prognosis. Typically insulin resistance and metabolic 74 
changes have been viewed as consequences of obesity.
6
 However increased peripheral 75 
insulin resistance and diabetes occur more frequently in neurodegenerative disease,
1,2-76 
5
 despite significant weight loss occurring in many of these disorders, often prior to 77 
diagnosis
7,8
 As such insulin resistance may be considered independently related to the 78 
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processes of neurodegeneration.
9,10
  (Figure 1) Common mechanisms associated with 79 
both metabolic dysfunction and neurodegeneration include oxidative stress, 80 
inflammation and vascular dysfunction.
10
 Whether these or alternate mechanisms 81 
promote metabolic dysfunction and neurodegeneration remains unclear. 82 
While there is limited in vivo evidence for the exact metabolic mechanism/s that may 83 
enhance neurodegeneration, there is emerging data on the metabolic variability 84 
associated with different neurodegenerative phenotypes. This is best highlighted by 85 
recent research in  amyotrophic lateral sclerosis (ALS) and frontotemporal dementia 86 
(FTD)  that suggests a spectrum of phenotypic metabolic changes that can be used as 87 
a model for studying such changes across other neurodegenerative conditions. The 88 
present article examines the eating and metabolic changes across the ALS and FTD 89 
spectrum and proposes a way forward for investigating metabolic disorders in these 90 
conditions in order to answer the critical question, namely whether metabolic 91 
derangements are the result, or conversely promote neurodegeneration. 92 
**Figure 1** 93 
The ALS and FTD clinical spectrum 94 
Mounting evidence points towards an overlap between ALS and FTD at clinical and 95 
neuropathological levels.
11
 These two conditions may be conceptualised as 96 
representing the extremes of a disease spectrum.
12,13
 Patients diagnosed with ALS 97 
typically exhibit limb or bulbar symptoms at initial presentation. (figure 2)
14-16
 There 98 
are varying reports on the incidence of cognitive changes in ALS (behavioural, 99 
cognitive, language) with estimates upwards of 5%
17,18
, while up to 15% of patients 100 
may satisfy the criteria for a diagnosis of concomitant FTD.
19
 Conversely, 10-15% of 101 
FTD patients have ALS, with varying estimates of motor neuron dysfunction in FTD 102 
insufficient to reach criteria for ALS, at between 25-30%.
12,20.
 FTD and ALS often 103 
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share a common pathology, TDP-43 protein deposition, which is present in the 104 
majority of ALS patients and in up to 50% of cases of FTD.
21
 This overlap has been 105 
further reinforced with the discovery of the C9orf72 gene abnormality in individuals 106 
with familial FTD and ALS.
22
 Recent research has suggested that these conditions 107 
may potentially result from a contiguous (almost ‘prion like’) spread 23,24,25 in a 108 
recognised centrifugal pattern with 4 stages of spread in ALS beginning in the motor 109 
neocortex, progressing to the spinal cord and brainstem, with involvement of frontal- 110 
parietal regions and finally the temporal lobes.
26
 Such a pattern of spread may further 111 
potentially explain the development of cognitive symptoms in ALS. In behavioural 112 
variant FTD (bvFTD) spread has been suggested to develop with a fronto-occipital 113 
gradient involving initially the frontal region, and then pre-motor, primary motor, 114 
parietal and occipital cortex.
27
 How this spread of pathology may occur and how it 115 
may further explain the spectrum of ALSFTD and the effect that metabolism may 116 
play, remains to be determined. The available evidence for eating and metabolic 117 
changes in ALS and FTD and potential affects on disease pathology, progression and 118 
survival is now reviewed. 119 
**Figure 2** 120 
Amyotrophic lateral sclerosis 121 
Eating behaviour and Nutritional intake in ALS 122 
Traditionally ALS has been regarded as a disease associated with malnutrition, with 123 
recent suggestions that nutritional intake decreases as the disease progresses, with 124 
decrease intake in those with lower functional levels,
28
 such that a high calorie diet 125 
and supplements may often be prescribed, with nutritional advice one of the major 126 
aspects of a multidisciplinary care model of management of ALS patients.
29-31
 Despite 127 
these recommendations, empirical evidence regarding optimal food intake levels in 128 
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ALS remains to be defined. It has been accepted that ALS patients may develop a 129 
reduced intake secondary to dysphagia,
32
 loss of appetite 
33
 and difficulty consuming 130 
food due to weakness of their hands. Recently it has also been determined that 131 
presymptomatic ALS patients may have increased total daily energy consumption 132 
compared to control subjects.
34
 Nutrition in ALS is arguably far more complex than 133 
these factors alone. The insufficient food intake typically reported by ALS patients 134 
may reflect increased catabolic demand and a state of hypermetabolism, and ALS 135 
patients may have increased caloric intake to overcome this. In extreme situations, 136 
some patients may develop severe complications of malnutrition including 137 
Wernicke’s encephalopathy.35 138 
There is limited evidence as to whether particular diets may slow progression of ALS. 139 
A high caloric diet is generally promoted and a recent study has shown that a high 140 
caloric, high carbohydrate diet is safe and tolerated by patients, but its effect on 141 
progression is yet to be identified. 
36
 Small studies have reported that a high 142 
carbohydrate diet and high fat diet results in stabilization of BMI, with no effect on 143 
functional decline (ALS functional rating scale -ALSFRS) and muscle mass.
37
 Studies 144 
in the SOD-1 mouse model
38
 have suggested that a high fat diet may be beneficial, 145 
but given that TDP-43 is the predominant pathology in this disease, generalizability to 146 
humans is limited. A number of clinical trials utilizing a high fat diet are currently 147 
underway to help address this question (Clinical trial reference numbers 148 
NCT02306590, NCT02152449 www.clinicaltrials.gov). A recent study utilizing 149 
protein supplementation resulted in increased BMI and stabilization of the ALSFRS 150 
suggesting a possible role for protein supplementation that requires further 151 
investigation as to whether the benefit was from the protein supplementation per se or 152 
the increased caloric intake that resulted.
39
 153 
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Percutaneous endoscopic gastrostomy (PEG) is offered to many ALS patients with 154 
bulbar involvement, in an effort to maintain nutrition and prevent further weight 155 
loss
40
. Despite this clinical approach, evidence of an overall benefit on survival 156 
remains limited, and the timing of insertion needs to be considered closely with the 157 
need to maintain nutrition and BMI against a typical backdrop of worsening 158 
respiratory function. It was recently determined by a multi-centre observational study 159 
that PEG tube placement was safe, even in those ALS patients with low forced vital 160 
capacity and that a slow increase in caloric rate and long term high caloric diet was 161 
associated with prolonged survival.
41
 Currently we are unable to advise patients on 162 
the ideal diet to slow progression in ALS, nor the effects that diet may have on 163 
metabolic changes. 164 
Metabolic changes in ALS 165 
Energy balance is a combination of intake (including food intake and nutrient 166 
absorption) and energy expenditure. Energy homeostasis is also intrinsically linked to 167 
glucose and lipid metabolism, with insulin being integral to cellular uptake of 168 
nutrients, and insulin resistance resulting in decreased sensitivity of peripheral cells 169 
(e.g. muscle) to nutrient uptake leading to decreased energy stores. ALS patients are 170 
generally lean and lose body mass, muscle mass and fat as the disease progresses 171 
leading to decreased energy store.
42
 These patients are also hypermetabolic, resulting 172 
in a complex interaction between energy metabolism, insulin and glucose 173 
homeostasis, lipid levels and BMI. 174 
Hypermetabolism 175 
Patients with ALS are consistently hypermetabolic, with increased resting energy 176 
expenditure evident in up to 50% of patients.
43,44
 This finding seems somewhat 177 
paradoxical, given that as the disease progresses patients develop denervation, muscle 178 
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atrophy, decreased muscle mass and decreased free fat mass, all of which would be 179 
expected to decrease energy expenditure.
43
 Several variables have been hypothesized 180 
to contribute to this hypermetabolic state, including uncontrolled fasciculations,
42
 181 
increased respiratory muscle work
45
 and mitochondrial dysfunction.
46
 It is also 182 
possible that the hypermetabolic state is intrinsically linked to the process of 183 
neurodegeneration with several genetic animal models exhibiting hypermetabolism 184 
and weight loss.
38,47-49
 Further compounding the issue are recent findings that energy 185 
expenditure in ALS patients using the doubly labeled water method are dependent on 186 
body composition and physical activity, meaning that some ALS patients may have 187 
reduced energy expenditure in advanced ALS. It remains to be determined what 188 
factors may modulate energy expenditure and how such factors may be incorporated 189 
into a clinical management paradigm.
50
 190 
Lipids 191 
The significance of hypercholesterolemia in ALS remains an ongoing source of 192 
debate, with questions remaining on whether there is an increased prevalence of 193 
hyperlipidaemia in ALS and its effect on progression and survival, with variations of 194 
reported results potentially secondary to factors including gender, ethnicity and BMI. 195 
In a French cohort of 369 patients with ALS, two thirds of patients had increased 196 
LDL cholesterol, decreased HDL concentration or a combination of the two.
51
 In the 197 
same cohort 38% had an elevated LDL to HDL ratio and increased concentrations of 198 
apolipoprotein E.
51
 In a German cohort elevated triglyceride and total cholesterol 199 
levels were associated with a positive effect on survival.
52
 Other studies have 200 
suggested that increased cholesterol levels may be associated with slower functional 201 
decline and increased survival,
53
 but these elevations in cholesterol levels may be 202 
gender specific, e.g. present only in females in a Japanese cohort.
53
  203 
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Alterations in lipid metabolism in ALS have been inconsistent, with several other 204 
studies suggesting that dyslipidaemia does not occur in ALS,
,54-56 ,
and is not 205 
associated with a benefit on survival,
55
 whilst in other studies, although patients were 206 
not dyslipidemic, having a higher HDL/LDL ratio was correlated with improved 207 
survival.
56
 In an Italian cohort poorer respiratory function was associated with lower 208 
cholesterol levels.
55
 These differences may be secondary to ethnic group, with low 209 
cholesterol levels or hypolipidemia being found in a population of Asian ethnicity.
54
 210 
Adding support to the hypothesis that cholesterol may play a modulating role in ALS 211 
is the finding in a number of epidemiological studies that treatment with statins results 212 
in an increased incidence of ALS.
57,58
 213 
The direct relationship between BMI and lipid levels has not being extensively 214 
investigated. One study has found that whilst LDL/HDL cholesterol ratio did not 215 
correlate with survival, the levels did not change over time or decrease with BMI, 216 
suggesting that for a given BMI the levels may remain elevated.
59
 217 
Why some ALS patients develop hyperlipidaemia and the effects on prognoses and 218 
pathogenesis remains unclear. Hyperlipidaemia could result from higher caloric 219 
intake and studies are needed correlating intake and cholesterol levels. Currently we 220 
do not know how lipid levels vary with BMI, gender and ethnicity and their 221 
subsequent effect on survival.  222 
Insulin resistance 223 
ALS was one of the first neurodegenerative conditions in which an association with 224 
insulin resistance was identified.
60
 Since then controversy has surrounded whether 225 
there is an increased incidence of diabetes and insulin resistance in ALS or whether 226 
diabetes may be protective for the onset of ALS and affect disease progression. The 227 
majority of the studies examining diabetes and ALS have been cross sectional and 228 
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single centre, meaning that the conclusions that can be derived are limited. Several 229 
studies
61,62
 have shown insulin resistance or diabetes may be protective with later 230 
onset of ALS in those with diabetes.
61
 A large Danish case control study found the 231 
estimated odds ratio (OR) for ALS in association with diabetes was 0.61 (95% 232 
Confidence Interval CI, 0.46-0.80).
63
 In a large Swedish case control study, type 2 233 
diabetes was associated with a decreased risk of ALS (OR 0.79, CI 0.68-0.91), 234 
whereas type 1 insulin dependent diabetes was associated with an increased risk (OR 235 
5.38, 95% CI 1.87-15.51), suggesting protective effects may be restricted to type 2 236 
diabetes which is associated with insulin resistance, rather than type 1 which has an 237 
autoimmune pathophysiology and may drive ALS. 
64,65
 238 
Recently a phase II clinical trial showed that pioglitazone, an oral anti-diabetic drug, 239 
as an add on therapy to riluzole, did not result in improved survival in ALS, and, in 240 
fact, resulted in a 21% increased hazard risk for mortality.
66
 It was hypothesized that 241 
this drug would be effective due to its anti-oxidant and anti-inflammatory properties. 242 
One reason why this effect was not seen could be secondary to its effect on insulin 243 
resistance and glucose homeostasis.
67
  244 
Despite these findings a number of other studies have suggested that whilst there may 245 
be an increased incidence of diabetes, it is not protective or a prognostic factor 246 
associated with ALS.
68
 A systematic review recently found an increased incidence of 247 
diabetes and insulin resistance, yet no effect on disease progression or survival.
69
 248 
Adding further controversy, a recent study in a Japanese population
70
 suggested an 249 
increased incidence of ALS in diabetics over a 9 year period with a HR of 1.35 (95% 250 
confidence interval [CI], 1.10– 1.67). This effect could be secondary to diabetes being 251 
an early marker of neurodegeneration, rather than driving the neurodegenerative 252 
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process, and further, that ALS patients may develop insulin resistance as a protective 253 
mechanism early on in the disease prior to diagnoses. 254 
In order to determine the association of diabetes and insulin resistance with ALS and 255 
whether this metabolic change drives neurodegeneration or is protective, large 256 
prospective longitudinal multiple centre studies will be required across multiple 257 
countries and ethnic groups. 258 
Body Mass Index 259 
Patients with ALS typically have a normal or low BMI
71
 and lose weight and body fat 260 
as the disease progresses,
72,73
 which in turn negatively affects prognosis.
74
 Low BMI 261 
in ALS has been attributed to a number of causes including loss of muscle mass,
42
 262 
swallowing difficulties, decreased nutritional intake
32
 and a state of 263 
hypermetabolism.
42
 It has also been suggested that the effect of BMI on survival in 264 
ALS may form a U–shaped relationship, with both low BMI and BMI > 35 associated 265 
with increased mortality, perhaps secondary to an increased incidence of 266 
cardiovascular disease.
59
 There are anecdotal reports of fat redistribution in ALS, with 267 
patients developing muscle wasting, loss of subcutaneous fat and increased abdominal  268 
fat with the amount of subcutaneous fat correlating with functional status and survival 269 
in ALS.
75
  270 
Lifestyle factors 271 
Premorbid BMI has been linked to the development of ALS, with lean individuals, 272 
those with high levels of increased leisure physical activity,
76
 and low premorbid 273 
BMI,
77,78
 at higher risk of ALS. Increased prediagnostic body fat has also been 274 
associated with decreased risk of ALS mortality.
73
 Whether prediagnostic BMI is 275 
predictive of the evolution of the disease in individuals diagnosed with ALS remains 276 
unknown..  277 
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Several studies have suggested that dietary modifications could decrease the risk of 278 
developing ALS and be protective. Interestingly, a high carbohydrate diet and low 279 
polyunsaturated fatty acid diet has been associated with an increased prevalence of 280 
ALS.
79
 These results seem counterintuitive given that a high carbohydrate diet would 281 
be expected to be related to a higher caloric intake and BMI, which should be 282 
protective. A more recent study  has suggested that a diet high in omega -3 283 
polyunsaturated fatty acids decreases the risk of ALS, suggesting that the results in 284 
the previous study may have been secondary to the low polyunsaturated fatty acid 285 
content.
80
 At this stage, no clear evidence exists as to which is the best diet to adopt to 286 
protect against ALS or change disease progression. Further large center studies are 287 
required to examine the effect of diet on preventing ALS. 288 
Frontotemporal dementia 289 
Eating behavior and nutritional intake in FTD 290 
 291 
The following sections focus on eating and metabolic changes in the other disease 292 
extreme FTD, where research when compared to ALS has focussed more on eating 293 
abnormalities and less on their metabolic effect thus far. FTD is characterized by 294 
atrophy of the frontal and anterior temporal lobes. Three main clinical syndromes of 295 
FTD are generally reported, namely  bvFTD and two language presentations, based 296 
on the predominant features at initial presentation. BvFTD is characterized by a 297 
marked deterioration in social function and personality. The language presentations 298 
are divided into fluent (semantic variant of primary progressive aphasia -svPPA) or 299 
nonfluent (nonfluent variant of PPA- nfPPA) variants, depending on the pattern of 300 
language and speech output deficits.
81,82
 301 
Hyperorality and dietary changes form one of the six criteria for the diagnosis of 302 
bvFTD
83
 and are reported in over 60% of patients at initial presentation
84
 and prove 303 
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helpful in diagnosing bvFTD and in discriminating this condition from other 304 
dementias such as Alzheimer’s disease.85 The changes in eating habits vary across the 305 
clinical subtypes of FTD. Alterations in bvFTD patients have been characterized by 306 
gluttony, hyperphagia, indiscriminate eating, and increased preference for sweet 307 
foods,
86-88
 as well as changes in appetite, food preference, eating habits and other oral 308 
behaviours compared to patients with Alzheimer’s disease.89 It is accepted that these 309 
changes in eating behaviour in FTD are complex and may be further confounded by 310 
cultural and ethnic factors that may influence eating behaviour.
90
 311 
In contrast, eating behaviour in svPPA has not been systematically examined until 312 
recently, perhaps reflecting the longstanding tradition of conceptualising svPPA as 313 
predominantly a language disorder. Typically svPPA patients have increased 314 
selectivity and food fads in their eating behaviour 
88
 and prominent changes in food 315 
preference and eating habits.
89,91
  316 
Swallowing abnormalities have been reported in all three subtypes of FTD, and are 317 
thought to be separate from compulsive eating behaviours and to reflect disruption of 318 
cortical and subcortical brain pathways connecting to the brainstem swallowing 319 
centre.
92
 They may also indicate early ALS, and have been found to influence 320 
prognosis.
92,93
 321 
The effects of changes in eating behaviour on carer stress and on the patients’ every 322 
day functional activity have not been investigated. Anecdotally, many carers report 323 
having to limit intake and place locks on fridge doors to limit patient intake. Our 324 
recent systematic examination of the eating changes in FTD using carer surveys 325 
revealed increased energy consumption in both bvFTD and svPPA patients.
91
 326 
Compared to controls, bvFTD patients had significantly increased carbohydrate 327 
intake, whereas svPPA patients displayed significantly increased sugar intake. Hunger 328 
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and satiety did not differ between bvFTD patients and controls, suggesting that 329 
alterations in hunger and satiety are not solely responsible for the abnormal eating 330 
behaviour in FTD. Other factors including cognitive behavioural changes, changes in 331 
reward processing, and pathological changes in neuro-endocrine systems are likely to 332 
contribute to alterations in eating behaviour in FTD.  333 
 334 
Proposed regional degeneration contributing to eating behaviour in FTD 335 
A number of studies have attempted to identify brain regions with greater 336 
neurodegeneration in bvFTD and svPPA patients, associated with abnormal eating 337 
behaviour. In bvFTD consistent regions identified were in a distributed set of 338 
frontoinsular and anteromedial temporal brain areas.
86,94
 These areas are similar to the 339 
areas involved in bvFTD,
95,96
 The pattern of change relating to eating behaviour 340 
suggests the disintegration of several networks rather than a specific structure being 341 
solely responsible for the behavioural change.  342 
Some studies have examined further specific eating behaviours and deficits in FTD. 343 
Binge eating in bvFTD patients has been associated with atrophy of the ventral 344 
aspects of the right insula, striatum and orbitofrontal cortex,
86
 which overlaps with 345 
regions involved in sweet preference (right anterior insula and bilateral orbitofrontal 346 
cortex)
94
 and reward seeking (right ventral putamen and pallidum). 
97
Patients with 347 
bvFTD and svPPA have been found to have deficits in flavour and odour 348 
identification, which link with degeneration in the left entorhinal cortex, 349 
hippocampus, and temporal pole.
98
 The hypothalamus is known to be critical for the 350 
regulation of food intake as it is integral to both the neuroendocrine and autonomic 351 
control systems of the brain.
99,100
 Atrophy of the posterior hypothalamus has been 352 
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associated with increased eating abnormalities in bvFTD
101,102
, however this atrophy 353 
is not present in sv-PPA patients with eating abnormalities.
103
 354 
Overall, these data support the concept that more than a single region is involved in 355 
the eating behaviours observed in FTD and that FTD subtypes may have degeneration 356 
in different parts of the same system producing overlapping behavioural 357 
abnormalities.. 358 
Gut hormones and hypothalamic neuropeptides regulating food intake in FTD  359 
The hypothalamus is influenced by circulating hormones and locally-produced  360 
neuropeptides that mediate appetite and eating behaviour: hormones and 361 
neuropeptides key to the appetite stimulating pathway include ghrelin (released 362 
peripherally) and agouti-related peptide (AgRP- released in the hypothalamus),
104
 363 
while key substances to the appetite suppressing pathway include  peripheral 364 
hormones leptin, peptide tyrosine tyrosine (PYY) and cholecystokinin (CCK)
105
 and 365 
key central neuropeptides pro-opiomelanocortin (POMC).
106-108
 366 
Studies on the appetite stimulating neuropeptides have found elevated levels of AgRP 367 
in both bvFTD and sv-PPA, and that AgRP levels were significantly associated with 368 
body mass index (BMI).
103
 This is consistent with the increased food intake and 369 
potential hyperphagia described as one of the main eating behaviours observed. AgRP 370 
is known to be a strong promoter of food intake,
104
 with administration of AgRP 371 
intracerebroventricularly in rats resulting in long-lasting hyperphagia.
109
 In addition to 372 
increasing total food intake in rats, AgRP may also lead to a preference for fat 373 
enriched food,
110
 and sucrose in the context of a high fat diet.
111
 374 
Two studies have examined the role of the appetite suppressing hormone leptin in 375 
FTD. The first found that women with FTD who were hyperphagic had higher 376 
circulating levels of leptin compared with women with Alzheimer’s disease. In 377 
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contrast, men with these disorders did not differ from controls in their leptin levels.
112
 378 
A second study found increased leptin levels in bvFTD patients exhibiting 379 
overeating.
113
 The increase in leptin should increase satiety and decrease food intake, 380 
however leptin is produced in adipose fat with its levels increasing secondarily to an 381 
increase in adipocyte mass and higher BMI, resulting in central leptin resistance, and 382 
this seems a more likely explanation for increased leptin levels found in FTD.  383 
It has been suggested that gut and hypothalamic hormonal changes in FTD may offset 384 
reward circuit dysfunction by regulating dopaminergic “top- down cognitive circuits” 385 
in compensation to overeating.
113
 Overall changes in the levels of these regulating 386 
peptide hormones in FTD subtypes may assist with understanding differences in the 387 
eating behaviours observed. The interaction between these central and peripheral 388 
systems (Figure 3 and Table 1) regulating eating behaviour (peptide hormones 389 
influencing the hypothalamus, neurons in the hypothalamus, networks impacting on 390 
the hypothalamus and reward pathways) will be important to determine for the 391 
different FTD phenotypes.  392 
***Table 1*** 393 
**Figure 3*** 394 
Metabolic changes in FTD 395 
 396 
Given the prominent changes in eating behavior in FTD it is not surprising that 397 
patients exhibit changes in BMI, insulin and cholesterol levels.  398 
Body Mass Index 399 
Recently it has been shown that both bvFTD (BMI= 29.65) and svPPA (BMI= 28.71) 400 
patients have increased BMI and waist circumference compared to normal controls 401 
(BMI= 24.05).
91
 It has been suggested that this weight gain is associated with their 402 
eating habits.
87
 Given the level of eating abnormalities in FTD, the question has been 403 
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raised in the literature as to why these patients do not have a higher BMI.
86
 It has been 404 
suggested that concomitant changes in metabolic rate similar to that seen in ALS may 405 
be present in FTD and may counteract some of the effect of these abnormal eating 406 
behaviours on BMI.
86
  407 
Lower body weight is observed in mouse models of FTD and ALS driven by a variety 408 
of genetic mutations, suggesting a secondary metabolic phenomenon from 409 
degenerative changes in a common set of vulnerable neurons.
114,115,116,117
 Eating 410 
behaviours in these mice have not been determined. Mouse models of FTD and ALS 411 
could have similar eating disturbances with increased food intake that results in lower 412 
body weight due to their increased metabolic rate. In humans a reduction in weight 413 
with increased caloric intake and increased metabolic rate could be observed. 414 
Changes in eating behavior with disease progression in bvFTD and sv-PPA may be 415 
further considered as metabolic change although evidence remains limited, and 416 
similarly how eating changes may progress longitudinally in FTD and their long-term 417 
effect on metabolism and BMI. 418 
 419 
Insulin resistance and lipids 420 
 421 
 Insulin resistance has been identified in both bvFTD and svPPA with increased 422 
insulin and triglycerides and lower HDL cholesterol (reflecting a state of insulin 423 
resistance).
118
 Importantly, more severe insulin resistance was associated with more 424 
severe eating abnormalities and higher BMI, and the changes in triglyceride and HDL 425 
cholesterol levels increase with disease progression.
118
 Increased insulin resistance is 426 
a risk factor for diabetes, and FTD patients also have an increased incidence of 427 
diabetes.
119
 The overall impact of these changes on disease progression and survival 428 
has not been explored, but is an important issue to consider, given the potential to 429 
17 
  
easily modify insulin and cholesterol levels with currently widely available 430 
medications. 431 
Could eating behavior and metabolic change influence survival in FTD and 432 
ALS? 433 
Given the clinical and pathological overlap between FTD and ALS,
12,120
  it would be 434 
reasonable to consider whether metabolic changes represented additional components 435 
of the overlap spectrum.
121
 At one end of the continuum, ALS patients develop weight 436 
loss, hypermetabolism, malnutrition, hyperlipidemia and insulin resistance. At the 437 
other end, patients with FTD develop insulin resistance, and potentially less weight 438 
gain than would be expected in light of their increased caloric intake.
86
  Further 439 
supporting the notion of the continuum between ALS and FTD (Figure 4), is the 440 
observation that ALS patients who develop additional cognitive deficits have an 441 
increased BMI compared to ALS patients without cognitive deficits.
121
 As such, these 442 
cognitively impaired ALS patients may mirror the eating changes described as typical 443 
in bvFTD, resulting in increased caloric intake and BMI.
122
  444 
In further support, it has recently been suggested that the structures involved in eating 445 
behaviour in bvFTD may also play a role in ALS, with pathological studies 446 
identifying TDP-43 pathology in the lateral hypothalamus in ALS that correlates with 447 
reduced BMI.
123
 It seems plausible that changes in the hypothalamus may reduce 448 
weight in ALS, and that patients who develop cognitive impairment in ALS may 449 
develop a spectrum of eating changes similar to those observed in bvFTD. This aspect 450 
may seem further enticing given that patients with the combination of FTD and ALS 451 
have a more rapid disease progression and poorer survival,
124,125
 suggesting a more 452 
aggressive disease process.  453 
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It remains to be determined how diet, ethnicity and BMI correlate with insulin, lipid 454 
and metabolic rate, perhaps contributing to the variation in results reported in the 455 
literature to date; and how such relationships may in turn influence disease 456 
progression and survival in FTD and ALS. Metabolic changes may reflect and also  457 
potentially modulate pathological progression along the clinical spectrum between 458 
ALS and FTD.
23
 Development of more exact animal models
126
 may promote 459 
examination of the process by which eating and metabolism affect pathological 460 
spread.
23
 Further understanding is required to determine whether metabolic 461 
differences vary with neuropathology, such as between TDP-43 which is most 462 
commonly identified in sv-PPA and ALS, when compared to bvFTD, which appears 463 
to be a mixture of TDP-43 and tau pathology. Given that many patients and carers ask 464 
about modifiable factors such as diet and lifestyle, clarification of these areas will 465 
enable the provision of targeted and accurate clinical advice. 466 
 467 
*** Figure 4*** 468 
 469 
Conclusion 470 
 471 
Are metabolic changes the result of or do they exacerbate neurodegeneration? 472 
 473 
The central question remains as to whether metabolic changes are the result or 474 
alternatively exacerbate neurodegeneration in ALS and FTD. These metabolic 475 
changes may represent an effect occurring secondarily to the process of 476 
neurodegeneration in critical brain regions, with some behavioural changes 477 
potentially serving as a protective influence. For example, the eating changes 478 
(hyperphagia) described in FTD may act as an adaptive mechanism to stave off a 479 
hypermetabolic state. Without more targeted research empirical evidence supporting 480 
either of these positions remains elusive. Further studies are required to document the 481 
relationship between eating behaviour and metabolic change in ALS and FTD. 482 
19 
  
Furthermore, critical analyses of disease progression and survival combining methods 483 
that examine the interaction between peripheral changes such as BMI, cholesterol and 484 
insulin levels, with central changes in brain structures, and the neuroendocrine 485 
changes,
127
 may bridge a better understanding between these factors. It remains to be 486 
determined how premorbid lifestyle factors and genetic factors interact and affect 487 
phenotypical expression, for example whether patients with high premorbid BMI go 488 
on to develop a phenotype with cognitive deficits whilst those with a low BMI 489 
develop pure ALS. We propose that targeted studies adopting a longitudinal approach 490 
across multiple disease groups, including affected and presymptomatic mutation 491 
carriers examining both eating behaviour and metabolism, should yield critical 492 
insights into the complex relationship between eating, metabolism and 493 
neurodegeneration.  494 
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Table 1: Neural and hormonal correlates of eating behaviour in FTD 909 
 910 
Study Factors implicated in 
eating behavior in FTD 
Measures used 
Miller and colleagues, 
1995 
87
 
Hypothesis: ? reduced 
hypothalamic serotonin 
release 
 
 
Carer questionnaire: weight 
gain, sweet/carbohydrate 
preference 
Ikeda and colleagues, 
2002 
89
 
Hypothesis: eating changes 
related to atrophy in ventral 
(orbito-basal) frontal lobe, 
temporal pole and 
amygdala 
Carer questionnaire: 
measuring 5 domains 
swallowing, appetite 
change, food preference, 
and eating habits  
Woolley and colleagues, 
2007
86
 
Outcome: binge eating 
associated with atrophy in 
the right ventral, insula, 
striatum and orbito-frontal 
cortex. 
Patient observation: 
Number of sandwiches 
eaten over 1 hour.   
Imaging: structural, Voxel 
Based Morphometry (VBM) 
Whitwell and colleagues, 
2007
94
 
Outcome: sweet tooth 
associated with grey matter 
loss in a distributed 
network including bilateral 
postero-lateral orbitofrontal 
cortex and right anterior 
insula. 
Hyperphagia associated 
with grey matter loss in 
anterolateral orbitofrontal 
cortex bilaterally 
Carer questionnaire: 
Manchester and 
Oxford Universities Scale 
for the Psychopathological 
Assessment 
of Dementia (MOUSEPAD) 
assessing hyperphagia and 
sweet preference. 
Imaging: structural, VBM 
Piguet and colleagues, 
2011
101
  
Outcome: those with high 
feeding disturbance had 
significant posterior 
hypothalamic atrophy  
Carer questionnaire: 
measuring 5 domains 
swallowing, appetite 
change, food preference, 
and eating habits 
Imaging: structural, manual 
tracing of hypothalamus  
Pathology: Hypothalamic 
volumes 
Omar and colleagues, 
2013
98
 
Outcome: flavour 
identification in the 
combined Frontal –
Patient observation: New 
test based on cross modal 
matching of flavours to 
29 
  
temporal lode degeneration 
cohort was associated with 
grey volume in the left 
entorhinal cortex, 
hippocampus, 
parahippocampal gyrus and 
temporal pole. 
words and pictures. 
Imaging: structural, VBM 
Perry and colleagues, 
2014
97
 
Outcome: overeating and 
sweet preference related to 
right hemispheric reward 
circuits including putamen, 
globus pallidus, insula and 
thalamus. 
Case note review: 
documenting hyperphagia 
and sweet preference 
Imaging: structural, VBM 
Woolley and colleagues 
2014
113
 
FTD associated with 
decreased ghrelin, cortisol 
and increased insulin. 
Patients who overate 
exhibited increased leptin 
levels 
Standardized lunch feeding 
session- total caloric intake 
calculated. 
Blood serum: 
neuroendocrine measures 
Bocchetta and 
colleagues, 2015
102
  
Outcome: atrophy of the 
superior parts of the 
anterior and tuberal regions 
and the posterior region, 
with a trend to association 
with abnormal eating 
behaviours 
Carer questionnaire: 
Cambridge behavioural 
inventory 
Imaging: structural, multi-
modal segmentation of 
hypothalamus on imaging 
Ahmed and colleagues, 
2015
103
 
Outcome: abnormal eating 
behaviours related to 
posterior hypothalamic 
atrophy. Elevated levels of 
Agouti-related protein in 
bvFTD and sv-PPA 
Carer questionnaire: 
measuring 5 domains 
swallowing, appetite 
change, food preference, 
and eating habits 
Imaging: manual tracing of 
hypothalamus 
Blood serum: 
neuroendocrine measures. 
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 913 
Figure 1: Metabolic changes in neurodegeneration 914 
 915 
Figure showing the metabolic changes documented in several neurodegenerative 916 
conditions and cross over between conditions, with multiple conditions showing 917 
insulin resistance and weight loss.
1-10
 918 
 919 
 920 
 921 
 922 
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Figure 2: Patterns of involvement in ALS. 923 
Figure showing the classical patterns of involvement in ALS
15,16 924 
Figure A: Atrophy affecting the first dorsal interossei (grey arrow), with sparing of 925 
the adductor digiti minimi (ADM- black arrow) and the classical split hand syndrome. 926 
Figure B: Wasting of the tibialis anterior and intrinsic muscles of the feet. Figure C: 927 
MRI brain (T1 and T2 sequences) showing hyperintensity of the cortical spinal tracts 928 
(grey arrow), suggesting upper motor neuron involvement as described in the original 929 
description of ALS by Charcot. 930 
 931 
Figure 3: Structures implicated in eating changes in FTD and control of eating in 932 
the normal individual  933 
 934 
Figure showing structures implicated in eating behavior in FTD and pathways 935 
controlling eating behavior in normal individuals. Structures implicated in FTD 936 
include orbito-frontal cortex, right sided reward structures including putamen, 937 
paillidum and striatum and posterior hypothalamus.
86, 97-103
 
 938 
 Normal eating behavior is controlled by an appetite stimulating pathway (shown in 939 
green) which results from ghrelin being released peripherally and targeting neurons of 940 
the arcuate nucleus (ARC) of the hypothalamus that contain neuropeptide Y (NPY) 941 
and agouti related peptide (AgRP). An appetite suppressing pathway involves leptin 942 
(shown in red) being released from peripheral adipocytes which then acts on pro-943 
opiomelanocortin (POMC) and the cocaine and amphetamine related transcript 944 
(CART) neurons in the hypothalamus. Peptide tyrosine tyrosine (PYY) and 945 
cholecystokinin (CCK), released peripherally also suppress appetite. AgRp, NPY, 946 
POMC and CART neurons in the hypothalamus project to act on melanocortin 947 
receptors (MCR). POMC is cleaved into alpha and beta melanocyte stimulating 948 
hormone that act on melanocortin receptor subtypes 3 and 4 (MCR 3 and 4) to 949 
31 
  
decrease food intake. AgRP stimulates food intake by antagonism of MCR 3 and 4 950 
receptors.
106-108
  In both bvFTD and sv-PPA elevated levels of AgRP have been 951 
found.
103
 Autonomic pathways (black arrow) are also involved in food intake through 952 
projections via the brainstem and cerebellum to the hypothalamus, PVN: 953 
paraventicular nucleus 954 
 955 
 956 
Figure 4: Eating and metabolic changes across the spectrum of ALS and FTD 957 
 958 
Visual representation of eating and BMI changes across the ALS and FTD spectrum. 959 
With decreased BMI and metabolic changes in ALS
42
, and as patients develop 960 
increasing cognitive impairment in ALS, increased BMI.
121
 FTD patients have 961 
increased BMI, but in the literature it has been suggested that this is less than 962 
expected for their caloric intake.
86
 Areas requiring further work (marked with ?) 963 
include the levels of caloric intake in ALS and whether FTD patients are also 964 
hypermetabolic.  ALS plus refers to ALS patients with cognitive and behavioural 965 
changes that do not yet meet the diagnostic criteria for FTD.  966 
 967 
